|Dr. Christopher U. Missling M.B.A., M.S., Ph.D.||Chairman, Pres, CEO & Sec.||708.6k||N/A||1966|
|Ms. Sandra Boenisch CPA, CPA, CGA||Principal Financial Officer & Treasurer||174.9k||N/A||1981|
|Mr. Stephan Toutain||Chief Operating Officer||N/A||N/A||1966|
|Dr. Walter E. Kaufmann M.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Clint Tomlinson||VP of Corp.||N/A||N/A||N/A|
|Dr. Adebayo Laniyonu Ph.D.||Sr. VP of Nonclinical Devel.||N/A||N/A||N/A|
|Dr. Edward R Hammond M.D., M.P.H., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Kun Jin Ph.D.||Head of Biostatistics||N/A||N/A||N/A|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp.’s ISS Governance QualityScore as of October 1, 2023 is 4. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 1; Compensation: 8.